HealthTech Marketing: Why Proof Beats AI Hype
Subscribe
HealthTech Report Urges CEOs to Replace AI Hype With Evidence and Visibility

digital marketing artificial intelligence

HealthTech Report Urges CEOs to Replace AI Hype With Evidence and Visibility

Business WireBusiness Wire

Published on : Nov 17, 2026

HealthTech startups may be approaching a communications turning point: describing a product as “AI-powered” is no longer enough to attract investors or earn media attention. A new report from SolComms and HLTH argues that founders seeking funding and visibility in 2027 need to demonstrate clinical evidence, measurable outcomes, regulatory awareness and a consistent public presence. Its analysis of 72 venture-backed U.S. healthcare startups suggests that many companies are still relying on generic messaging while overlooking the proof points investors and reporters want to see.

HealthTech companies have spent recent years incorporating artificial intelligence into their products and positioning. But as AI language becomes commonplace across healthcare technology pitches, the phrase “AI-powered” appears to be losing its ability to differentiate startups.

That is the central message of The HealthTech Attention Economy Report, released by public relations agency SolComms in partnership with HLTH at HLTH 2026. The report examines how healthcare technology founders communicate their value to investors and journalists, focusing on messaging clarity, differentiation, evidence and policy awareness.

The research used an AI-supported analysis developed with Trash Marketing to assess the public communications of 72 U.S.-based, venture-backed HealthTech startups at Series A through Series C. The companies were selected from approximately 1,600 healthcare businesses that applied to speak at HLTH 2026. The report also incorporates perspectives from surveyed venture capitalists and healthcare reporters.

Its findings point to a disconnect between how startups describe themselves and what influential audiences say they need to evaluate them. Nearly three-quarters of the companies analyzed lead their messaging with “AI-powered,” yet none of the surveyed investors said the phrase increased their confidence in a company. Reporters also identified it as one of the most overused expressions in startup pitches.

The finding does not suggest that AI capabilities are irrelevant to healthcare buyers or investors. Rather, it indicates that the technology label alone provides limited information about a company's clinical value, commercial readiness or ability to solve a specific healthcare problem. Founders need to explain what their technology does, which outcomes it improves and what evidence supports those claims.

The report places particular emphasis on founder visibility and storytelling. Every investor surveyed considered a founder's ability to tell a compelling story critical to funding decisions. For reporters, a company executive who can explain industry developments and offer a clear perspective may be more useful than a conventional product pitch.

LinkedIn is highlighted as an important channel for building that visibility. The report suggests that executives who participate consistently in industry conversations can become more recognizable to journalists and investors. This places owned media and executive communication alongside traditional press coverage as parts of a broader reputation-building strategy.

Policy awareness is another identified weakness. Only 14% of the startups analyzed referenced any of the 11 core policy terms and topics tracked by the report, including the FDA, Affordable Care Act, drug pricing and MAHA. Yet reporters surveyed identified policy and regulatory developments as subjects that can generate strong reader interest.

For healthcare startups, policy literacy can help explain how a product fits into the operating environment of providers, payers and patients. Regulatory milestones, reimbursement developments and evidence of clinical effectiveness can also provide more substantive communications material than broad claims about innovation.

The report's recommendations reflect a wider shift in HealthTech communications: visibility increasingly depends on the quality of the evidence and perspective behind a company's message. As startups compete for capital, customers and media attention, consistent executive presence may help them get noticed, but credible proof is needed to support the attention they attract.

Market Landscape

The report arrives as healthcare technology companies face pressure to demonstrate that their products deliver value beyond technical novelty. AI capabilities have become widespread across clinical workflows, patient engagement, diagnostics, administration and healthcare operations. As a result, broad claims about automation or intelligence may offer less differentiation unless supported by specific use cases and evidence.

The emphasis on proof also reflects the scrutiny applied to healthcare-related claims. The U.S. Federal Trade Commission says objective health-related product claims require adequate substantiation, with scientific evidence appropriate to the nature of the claim. This makes clinical validation and transparent communication important not only for investor relations and media engagement, but also for responsible marketing.

 

For startups, the challenge is to communicate technical differentiation without overstating clinical or commercial results. Regulatory milestones, reimbursement progress, peer-reviewed research and independently validated outcomes can provide more concrete signals than generic innovation language.

Strategic Outlook

The report suggests that HealthTech communications strategies in 2027 will need to connect three elements: a clear explanation of the problem being solved, evidence that the solution works, and visible leadership capable of explaining its wider relevance.

Founders should also distinguish between visibility and credibility. LinkedIn activity, media coverage and conference participation can increase recognition, but sustained attention depends on useful insights and verifiable information. Policy awareness may create additional opportunities for companies operating in regulated markets, particularly when they can explain how changes affect providers, payers and patients.

There are limits to the report's findings. Its company analysis covers 72 U.S.-based, venture-backed startups at Series A to C, selected from companies that applied to speak at HLTH 2026. The investor and reporter perspectives are based on the respondents surveyed, rather than a representative sample of the entire healthcare investment and media industries.

Even with those limitations, the findings offer a practical communications signal: as AI terminology becomes commonplace, HealthTech companies need to explain their value with greater precision. Technology may attract initial interest, but evidence, relevance and credible leadership are what help sustain it.

Top Insights

  • AI messaging is losing differentiation: 72% of analyzed startups lead with “AI-powered,” but none of the surveyed investors said the phrase increased their confidence.

  • Evidence matters to investors and reporters: Clinical data, measurable outcomes and third-party validation offer more substantive support than broad claims about technological innovation.

  • Founder visibility influences attention: Investors value compelling executive storytelling, while consistent participation in industry conversations can help founders become recognizable sources.

  • Policy awareness is underused: Only 14% of analyzed companies referenced the report's tracked policy topics, despite reporter interest in regulatory and reimbursement developments.

  • Communications need multiple proof points: HealthTech startups must connect clear positioning with evidence, policy understanding and a consistent presence across earned and owned channels.

Get in touch with our MarTech Experts

Looking to publish a press release, guest article, interview or podcast? Connect with us.

GET FEATURED